US Stock MarketDetailed Quotes

PALI Palisade Bio

Watchlist
  • 2.2800
  • -0.1200-5.00%
Close Dec 3 16:00 ET
  • 2.3400
  • +0.0600+2.63%
Post 19:55 ET
3.03MMarket Cap-171P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    4 hours ago
    🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.
    Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...
    3
    1
    Jaguar8
    Jaguar8
    13 hours ago
    NEWS
    $Palisade Bio (PALI.US)$
    Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
    Tuesday, 3rd December at 8:15 am
    First three Single Ascending Dose cohorts demonstrated no treatment related adverse events
    Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (NASDAQ: PALI) ("Palisade," "Palisade Bio" or the "Company"), a clinical-stage biop...
    Jaguar8
    Jaguar8
    Nov 21 07:16
    NEWS
    $Palisade Bio (PALI.US)$
    Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
    Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit
    PALI-2108 may offer a solution for fibrostenotic Crohn's disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments
    Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, a clinical-stag...
    Jaguar8
    Jaguar8
    Nov 12 07:47
    NEWS ER
    $Palisade Bio (PALI.US)$
    Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
    Positive
    Initiated Phase 1 clinical trial with patient enrollment and dosing for PALI-2108
    Received European patent notice for PALI-2108 and PALI-1908
    Completed first GMP batch of PALI-2108 drug substance
    Successfully demonstrated ex vivo bioactivation in clinical studies
    Negative
    None.
    Jaguar8
    Jaguar8
    Oct 31 07:31
    NEWS
    $Palisade Bio (PALI.US)$
    Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
    Palisade Bio (NASDAQ: PALI) has presented positive data from two ex vivo translational studies of PALI-2108, their colon-specific PDE4 inhibitor prodrug for ulcerative colitis treatment. The studies demonstrated successful bioactivation in stool samples and significant TNFα inhibition in whole blood. PALI-2108achieved a 90.1% conversion rat...
Read more
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
Meta Platforms
META
+3.51%
Coinbase
COIN
+2.30%
Amazon
AMZN
+1.30%
Apple
AAPL
+1.28%
Oracle
ORCL
+0.82%

Unlock the Full List